SKAN Group AG (SKAN) AI Stock Analysis

• Market Cap: CHF1.33B
• Dividend Yield: 0.68%
• Average Volume (3M): 35.30K
• Price to Earnings (P/E): 82.1
• Beta (1Y): 0.88
• Revenue Growth: -3.45%
• EPS Growth: -49.82%
• Country: CH
• Employees: 1,377
• Sector: Services
• Sector Strength: N/A
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.40
• Shares Outstanding: 22,483,524
• 10 Day Avg. Volume: 30,386
• 30 Day Avg. Volume: 35,298
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF82.67
• Price Target Upside: 41.80% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 67 Neutral
• Price Target: CHF76.00 ▲(30.36% Upside)

SKAN Group AG's overall stock score is influenced primarily by strong financial performance and stable operations. However, the high P/E ratio indicates a premium valuation, and technical indicators suggest potential short-term price pressure. Cash flow challenges and limited dividend yield further moderate the overall score.

SKAN Group AG Business Overview & Revenue Model

Company Description

SKAN Group AG provides isolators, cleanroom devices, and decontamination processes for pharmaceutical and chemical industries in Asia, Europe, the Americas, and internationally. It operates in two segments: Equipment and Solutions (E&S) and Services and Consumables (S&C). The E&S segment offers mission-critical solutions for the pharmaceutical production, including isolators, integrated automated systems, and aseptic filling systems and solutions, as well as laboratory and cleanroom equipment. The S&C segment provides life cycle support and ready-to-use consumables, as well as customer- specific and digital solutions. The company was formerly known as BV Holding AG and changed its name to SKAN Group AG in October 2021. SKAN Group AG was founded in 1968 and is headquartered in Allschwil, Switzerland.

How the Company Makes Money

SKAN Group AG generates revenue primarily through the sale of its specialized cleanroom and isolation technology products to pharmaceutical and biotechnology companies. These products are essential for ensuring sterile environments in drug manufacturing and research facilities. In addition to product sales, SKAN offers related services such as installation, maintenance, and consulting, which provide additional revenue streams. The company may also engage in strategic partnerships and collaborations with industry leaders to enhance its product offerings and expand its market presence, further contributing to its earnings.

SKAN Group AG Financial Statement Overview

Summary

SKAN Group AG exhibits a strong financial performance with impressive revenue and profit growth. The company maintains operational efficiency and has a stable balance sheet. However, cash flow management requires improvement, especially concerning capital expenditures.

Income Statement

SKAN Group AG has demonstrated strong revenue growth, with Total Revenue increasing consistently over the years. The Gross Profit Margin and Net Profit Margin have remained robust, indicating effective cost management and profitability. The EBIT and EBITDA margins are healthy, showcasing operational efficiency. Overall, the company displays a solid income statement performance with positive growth trends.

Balance Sheet

The company's balance sheet is stable, supported by a reasonable Debt-to-Equity Ratio, indicative of prudent leverage levels. The Return on Equity is strong, reflecting good profitability relative to equity. The Equity Ratio shows a solid equity base compared to total assets, enhancing financial stability. However, some attention is needed on total liabilities, which have grown over time.

Cash Flow

SKAN Group AG's cash flow performance is mixed, with fluctuating free cash flow levels. The Operating Cash Flow to Net Income Ratio is favorable, showing effective cash generation from operations. However, recent negative Free Cash Flow suggests high capital expenditures impacting cash reserves. The company needs to manage investing activities to maintain liquidity.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	361.30M	320.02M	276.95M	234.26M	191.69M
Gross Profit	265.88M	234.08M	200.50M	170.11M	133.00M
EBITDA	59.68M	50.14M	40.15M	32.38M	16.48M
Net Income	38.80M	26.31M	18.99M	21.40M	11.59M
Balance Sheet
Total Assets	384.49M	373.45M	388.35M	331.92M	259.54M
Cash, Cash Equivalents and Short-Term Investments	61.71M	85.12M	110.98M	131.54M	63.82M
Total Debt	10.61M	6.49M	16.88M	15.27M	7.45M
Total Liabilities	181.92M	197.09M	222.76M	157.92M	176.98M
Stockholders Equity	196.16M	169.23M	157.30M	159.75M	41.65M
Cash Flow
Free Cash Flow	-7.09M	-26.60M	32.62M	-32.29M	8.07M
Operating Cash Flow	46.70M	8.70M	61.48M	10.32M	22.63M
Investing Cash Flow	-69.06M	-17.35M	-76.42M	-11.02M	-15.95M
Financing Cash Flow	-9.35M	-15.80M	-4.85M	67.48M	-8.15M

SKAN Group AG Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 58.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:SKAN, the sentiment is Negative. The current price of 58.3 is below the 20-day moving average (MA) of 64.73, below the 50-day MA of 69.21, and below the 200-day MA of 71.72, indicating a bearish trend. The MACD of -2.80 indicates Positive momentum. The RSI at 24.99 is Positive, neither overbought nor oversold. The STOCH value of 5.70 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:SKAN.

SKAN Group AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SFSN	71 Outperform	CHF4.20B	17.59		1.85%	-0.71%	-6.12%
STMN	68 Neutral	CHF15.08B	38.40		1.02%	4.49%	45.08%
SKAN	67 Neutral	CHF1.33B	82.14		0.68%	-3.45%	-49.82%
COTN	58 Neutral	CHF1.32B	33.59		0.86%	27.24%	122.39%
Sector *	56 Neutral	$13.75B	13.24	10.03%	0.92%	7.13%	-12.93%
TCHBF	―	$2.48B	33.50	4.57%	1.91%	―	―
0QLQ	―	CHF5.47B	61.33	13.49%	0.55%	―	―

SKAN Group AG Corporate Events

SKAN Group Expands Digital Capabilities with Metronik Acquisition

SKAN Group AG has acquired a majority stake in Metronik d.o.o., a leading provider of software solutions for production digitization in the life sciences industry. This acquisition enhances SKAN’s capabilities by integrating Metronik’s modular software platform, which supports the complete digitization of pharmaceutical production processes. The move positions SKAN as a comprehensive solution provider in the pharmaceutical value chain, promising immediate value contribution and strengthening its industry positioning.

The most recent analyst rating on (CH:SKAN) stock is a Buy with a CHF92.00 price target. To see the full list of analyst forecasts on SKAN Group AG stock, see the CH:SKAN Stock Forecast page.

SKAN Group AG Acquires Majority Stake in Metronik to Boost Digital Services

SKAN Group AG has announced the acquisition of a 76% stake in Metronik d.o.o., a Slovenian company specializing in digital and automated systems for the life sciences sector. This acquisition is expected to enhance SKAN’s digital service portfolio, strengthen its Services & Consumables segment, and positively impact earnings per share in 2025. Metronik’s expertise in software solutions for production management and digital transformation aligns with SKAN’s strategic objectives to accelerate digital transformation and improve operational efficiency. The acquisition is anticipated to close in the third quarter of 2025, subject to regulatory approvals.

The most recent analyst rating on (CH:SKAN) stock is a Buy with a CHF92.00 price target. To see the full list of analyst forecasts on SKAN Group AG stock, see the CH:SKAN Stock Forecast page.

SKAN Group Unveils Growth Strategy and New Services at Capital Markets Day

SKAN Group AG held its first Capital Markets Day, highlighting its growth strategy and the introduction of Pre-Approved Services. The company aims to expand market leadership through investments in key competencies, innovation, and digital transformation. SKAN plans to increase revenue from aftermarket services and consumables, with a focus on maintaining its unique corporate culture. The new Pre-Approved Services facility will allow customers to conduct early stability tests for drug approval, significantly reducing time to market and providing a competitive edge.

The most recent analyst rating on (CH:SKAN) stock is a Buy with a CHF92.00 price target. To see the full list of analyst forecasts on SKAN Group AG stock, see the CH:SKAN Stock Forecast page.

SKAN Group AG Annual General Meeting Approves All Proposals

At its Annual General Meeting, SKAN Group AG received approval for all board proposals, including a dividend distribution of CHF 0.40 per share. The re-election of board members and approval of compensation and non-financial reports were also confirmed, reflecting strong shareholder support and stability in leadership.